Company / Operating Cash Flow
Ultragenyx Pharmaceutical Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$466.0M
FY2025
5-year range
-$475.0M / -$345.4M
FY2021-FY2025
Trend
-12.6%
vs FY2024
Sector context
#207 of 216
Health Care
What the data says
Among 216 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the bottom 4% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$475M in FY2023 to -$45M in FY2016.
Based on SEC 10-K filings.
-$466M in FY2025.
Remained stable around -$466M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 216This company -$466.0M Sector average $658.7M
▼
-170.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 12.6% year-over-year.
- Ranks #207 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$466.0M | -12.6% |
| FY2024 | -$414.0M | +12.8% |
| FY2023 | -$475.0M | -24.8% |
| FY2022 | -$380.5M | -10.2% |
| FY2021 | -$345.4M | -18.9% |
| FY2020 | -$290.6M | -14.5% |
| FY2019 | -$253.8M | +12.6% |
| FY2018 | -$290.6M | -174.2% |
| FY2017 | -$106.0M | -137.4% |
| FY2016 | -$44.6M | +57.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026